Scholar Rock Holding Corp

Scholar Rock Holding Corp. is a biopharmaceutical company. It engages in the development and discovery of innovative medicines. The firm offers proprietary platform which designed to discover and develop monoclonal antibodies that have a high degree of specificity to achieve selective modulation of growth factor signaling. Its product candidate includes SRK-015 and SRK-181. The company was founded by Timothy A. Springer and Leonard I. Zon in October 2012 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Scholar Rock advances myostatin programs, eyes regulatory milestones in 2024

Scholar Rock's Q3 performance reflects progress in myostatin programs and expansion into cardiometabolic disorders, supported by strong financials and partnerships.
The company's focus on myostatin biology, promising results of apitegromab and SRK-439, and engagement with regulatory authorities position them for future success.
While facing challenges in statistical assumptions, patient variability, and therapy safety, Scholar Rock's deep understanding of myostatin presents opportunities for growth and innovation.

Scholar Rock excels in Q3 with SMA breakthrough and strong financial backing

Scholar Rock's Q3 performance showcases promising advancements in SMA treatment and strategic initiatives to drive future growth and commercial success.
The company's strong financial position, diverse pipeline, and focus on patient-centric care position them well for potential market leadership.
While facing challenges in regulatory approval and market competition, Scholar Rock's proactive approach and innovative drug candidates present significant opportunities for growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Scholar Rock Holding Corp. is a biopharmaceutical company. It engages in the business of discovering, developing, and delivering innovative medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company was founded by Timothy A. Springer and Leonard I. Zon in October 2012 and is headquartered in Cambridge, MA.

Scholar Rock Holding Corporation (SRRK) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

All You Need to Know About Scholar Rock Holding Corporation (SRRK) Rating Upgrade to Strong Buy

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a Phase 3, clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced that management will host a conference call to discuss its third quarter 2023 financial results and provide a business update on Tuesday, November 7, 2023, at 8:00 a.m. ET. To access the conference call by phone, participants may register here to receive the dial-i.

Scholar Rock to Host Conference Call to Discuss Third Quarter 2023 Financial Results and Provide Business Update on November 7, 2023

The average of price targets set by Wall Street analysts indicates a potential upside of 204% in Scholar Rock Holding Corporation (SRRK). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Wall Street Analysts Think Scholar Rock Holding Corporation (SRRK) Could Surge 203.99%: Read This Before Placing a Bet

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a Phase 3 clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, announced today that it will present data from DRAGON, a Phase 1 study of SRK-181 in patients with advanced solid tumors at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting in San Diego on November 1-5. In one poster presentation, Scholar Rock will share prelimina.

Scholar Rock to Present Clinical and Biomarker Data from the Phase 1 DRAGON Trial at the SITC 38th Annual Meeting

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock Holding Corporation (Nasdaq: SRRK), a Phase 3 clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced the closing of its previously announced underwritten public offering of 14,270,074 shares of common stock, which includes the exercise in full by the underwriters of their option to purchase an additional 1,861,314 shares, at the public offering.

Scholar Rock Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares

Scholar Rock (SRRK) rises on plans to advance SRK-439 for treating obesity and offering common stock.

Scholar Rock (SRRK) Up on Pipeline Advancement, Stock Offering

Scholar Rock announced it will advance the development of its obesity treatment, SRK-439, starting with a phase 2 proof-of concept trial in 2024. The biopharma company will work toward an investigational new drug (IND) application submission in 2025.

Why Scholar Rock Holding Stock Soared Today

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock Holding Corporation (Nasdaq: SRRK), a Phase 3 clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced the pricing of an upsized underwritten public offering of 12,408,760 shares of its common stock at a public offering price of $6.85 per share. The aggregate gross proceeds to Scholar Rock from this offering are expected to be approximately $85.0.

Scholar Rock Announces Pricing of Upsized Public Offering of Common Stock

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock Holding Corporation (Nasdaq: SRRK), a Phase 3 clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced that it has commenced an underwritten public offering for $75.0 million of shares of its common stock. All of the shares are being offered by Scholar Rock. In addition, Scholar Rock intends to grant the underwriters a 30-day option to purchase ad.

Scholar Rock Announces Proposed Public Offering of Common Stock

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a Phase 3, clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced it plans to advance SRK-439, a novel investigational myostatin inhibitor for the treatment of obesity towards an investigational new drug application (IND) submission in 2025. As part of the Company's strategy to advance the development of SRK-439, it plans to init.

Scholar Rock to Advance Antimyostatin Program to Develop Novel Therapies for Cardiometabolic Disorders

AMC Entertainment

Owens-Illinois

Sera Prognostics

Valens Semiconductor Ltd

Tap four stocks with increasing P/E ratios to try out an out-of-the-box approach. These stocks include AMC Entertainment (AMC), Scholar Rock (SRRK), PTK Acquisition (VLN), OI Glass (OI) and Sera Prognostics (SERA).

Why You Should Bet on 4 Top-Ranked Stocks With Rising P/E

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a Phase 3 clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, announced today that it has completed enrollment of the SAPPHIRE Phase 3 trial evaluating the safety and efficacy of apitegromab in nonambulatory patients with Types 2 and 3 spinal muscular atrophy (SMA) who are receiving SMN therapy (either nusinersen or risdiplam). The company al.

Scholar Rock Announces Completion of Enrollment for the Phase 3 SAPPHIRE Trial

The mean of analysts' price targets for Scholar Rock Holding Corporation (SRRK) points to a 264.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Wall Street Analysts Believe Scholar Rock Holding Corporation (SRRK) Could Rally 264.53%: Here's is How to Trade

Scholar Rock Holding Corp. is developing a growth factor targeted therapy called apitegromab for Spinal Muscular Atrophy. Positive interim data from a phase 2 trial showed sustained improvement in motor function for non-ambulatory SMA patients receiving apitegromab. Apitegromab works differently from other approved SMA treatments and claims longer duration of treatment effect and improved muscle function.

Scholar Rock: The Market Isn't Enthusiastic Despite Decent Clinical Data

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a Phase 3 clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today reported financial results and corporate updates for the second quarter ended June 30, 2023. “We continue to advance our apitegromab program, notably with the recent presentation of 36-month data from the Phase 2 TOPAZ trial which supports apitegromab's therapeutic potential.

Scholar Rock Reports Second Quarter 2023 Financial Results and Highlights Business Progress

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a Phase 3, clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced new data from the Phase 2 TOPAZ trial extension period evaluating patient outcomes at 36 months of treatment with apitegromab. These data showed that continued treatment with apitegromab over the extended treatment period was associated with substantial and sustain.

New 36-Month Apitegromab Extension Data Reinforce Long-Term Substantial and Sustained Improvement of Motor Function in Phase 2 TOPAZ Trial Patients with Nonambulatory Spinal Muscular Atrophy

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a Phase 3 clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced that management will present at the Jefferies Healthcare Conference on Thursday, June 8, 2023, at 3:00 p.m. ET. A live webcast of the presentation may be accessed by visiting the Investors & Media section of the Scholar Rock website at http://investors.scholarro.

Scholar Rock to Present at the Jefferies Healthcare Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a Phase 3 clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today reported financial results and corporate updates for the first quarter ended March 31, 2023. “We are executing across our business and leveraging Scholar Rock's differentiated platform, which selectively targets latent forms of growth factors, such as myostatin and TGFβ1, to.

Scholar Rock Reports First Quarter 2023 Financial Results and Highlights Business Progress

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a Phase 3, clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, announced today it will present extension data from the Phase 2 TOPAZ trial evaluating patient outcomes after 36 months of treatment with apitegromab. Apitegromab is an investigational antibody inhibiting myostatin activation by selectively binding the pro- and latent forms of myo.

Scholar Rock to Present New Data Evaluating Apitegromab at 36 Months from the Phase 2 TOPAZ trial at the 2023 Annual Cure SMA Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a Phase 3 clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced that Richard Brudnick, has been appointed to Scholar Rock's Board of Directors as an independent director. Mr.

Scholar Rock Announces the Addition of Richard Brudnick to Its Board of Directors

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a Phase 3 clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today reported financial results and corporate updates for the full year ended December 31, 2022. “2023 is off to a great start as we continue to build upon our momentum from last year.

Scholar Rock Reports Full Year 2022 Financial Results and Highlights Business Progress

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a Phase 3, clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced it will present data from its Phase 2 TOPAZ trial extension period evaluating patient outcomes after 24 months of treatment with apitegromab, an investigational selective inhibitor of the activation of myostatin for spinal muscular atrophy (SMA).

Scholar Rock to Present 24-Month Data from the Phase 2 TOPAZ trial at the 2023 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a Phase 3 clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced that management will present at the Cowen 43rd Annual Health Care Conference on Tuesday, March 7, 2023, at 12:50 p.m. ET.

Scholar Rock to Present at the Cowen 43rd Annual Health Care Conference

CAMBRIDGE, Mass.--( BUSINESS WIRE )--Scholar Rock (NASDAQ: SRRK), a Phase 3 clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced the appointment of Tracey M. Sacco as Chief Commercial Officer. Ms. Sacco brings extensive biopharmaceutical industry experience, including product launch and global commercial strategy. At Scholar Rock, she will build and lead all commercial functions, including sales, marketing, market access, and commercial operations. Her first priority will be preparing the company for the potential commercial launch of apitegromab, the company's Phase 3 investigational candidate for spinal muscular atrophy (SMA).

Scholar Rock Appoints Tracey M. Sacco as Chief Commercial Officer

CAMBRIDGE, Mass.--( BUSINESS WIRE )--Scholar Rock (NASDAQ: SRRK), a Phase 3 clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today provided recent corporate updates and highlighted upcoming priorities for its pipeline programs in 2023.

News for Scholar Rock Holding Corp Stock (SRRK)